Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 5-day suspension order for the drug license of a store located in Dinnur, Karnataka. The order was issued by the Assistant Director, Drugs Control Administration, Bangalore Circle-05, under Rule 65 of the Drugs and Cosmetics Act, 1940, and was received on May 6, 2025. The company estimates a potential revenue loss of approximately Rs 5.61 lakhs from this suspension. The disclosure was made on May 7, 2025, in compliance with SEBI Listing Regulations.
The financial impact is negligible at around Rs 5.61 lakhs, and only a single store is affected for five days, so this is unlikely to materially affect the company's operations or stock price.